Dataset Information

Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.

ABSTRACT: BACKGROUND:Genetic variation of SNPs in the PTGS2 gene is reported to be capable of creating tissue milieu favoring tumorigenesis. Some studies have implicated the common SNP rs20417 has association with PCa risk, while others showed reverse results. The study was performed with an aim to reconcile the existing controversy by performing a meta-analysis. METHODS:We searched databases of Embase and PubMed and identified 8 publications fulfilling the specified inclusion criteria. X(2)-based Q-test and I(2) statistic were quantified to measure the heterogeneity across studies. The pooled ORs and 95% CIs were calculated to estimate the association between SNP rs20417 and PCa risk. RESULTS:Based on an enlarged sample size by combining the data from published meta-analyses and those missed in them, the results of the present meta-analysis revealed the association of SNP rs20417 and overall PCa risk was not significant. Subgroup analyses according to ethnicity and source of controls did not show any significant results, either. CONCLUSIONS:The meta-analysis suggests that the presence of SNP rs20417 is unlikely to be associated with PCa risk. Our understanding of the genetic risk for PCa should be further expanded and refined through future research in a much larger number of participants.

SUBMITTER: Zhang L

PROVIDER: S-EPMC4723806 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.

Zhang Lei L Zhang Yan Y Zhang Xu X Hong Baofa B

International journal of clinical and experimental medicine 20151115 11

<h4>Background</h4>Genetic variation of SNPs in the PTGS2 gene is reported to be capable of creating tissue milieu favoring tumorigenesis. Some studies have implicated the common SNP rs20417 has association with PCa risk, while others showed reverse results. The study was performed with an aim to reconcile the existing controversy by performing a meta-analysis.<h4>Methods</h4>We searched databases of Embase and PubMed and identified 8 publications fulfilling the specified inclusion criteria. X(2 ...[more]

PMID: 26884961

Similar Datasets

Project description:BACKGROUND: Resection of colorectal cancer liver metastasis (CRCLM) with curative intent has long-term benefit in ~40% of cases. Prognostic biomarkers are needed to improve clinical management and reduce futile surgeries. Expression of epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2; also known as cyclooxygenase-2) has been associated with carcinogenesis and survival. We investigated the prognostic value of EGFR and PTGS2 expression in patients with resected CRCLM. METHODS: Formalin-fixed paraffin-embedded CRCLM tissue and corresponding primary tumour specimens from a multi-institutional cohort of patients who underwent liver resection between 1990 and 2010 were incorporated into tissue microarrays (TMAs). TMAs were stained for EGFR and PTGS2 by immunohistochemistry. The hazard rate ratio (HRR) for the association between expression in CRCLM and overall survival was calculated using a 500-fold cross-validation procedure. RESULTS: EGFR and PTGS2 expression could be evaluated in 323 and 351 patients, respectively. EGFR expression in CRCLM was associated with poor prognosis (HRR 1.54; P<0.01) with a cross-validated HRR of 1.47 (P=0.03). PTGS2 expression was also associated with poor prognosis (HRR 1.60; P<0.01) with a cross-validated HRR of 1.63 (P<0.01). Expression of EGFR and PTGS2 remained prognostic after multivariate analysis with standard clinicopathological variables (cross-validated HRR 1.51; P=0.02 and cross-validated HRR 1.59; P=0.01, respectively). Stratification for the commonly applied systemic therapy regimens demonstrated prognostic value for EGFR and PTGS2 only in the subgroup of patients who were not treated with systemic therapy (HRR 1.78; P<0.01 and HRR 1.64; P=0.04, respectively), with worst prognosis when both EGFR and PTGS2 were highly expressed (HRR 3.08; P<0.01). Expression of PTGS2 in CRCLM was correlated to expression in patient-matched primary tumours (P=0.02, 69.2% concordance). CONCLUSIONS: EGFR and PTGS2 expressions are prognostic molecular biomarkers with added value to standard clinicopathological variables for patients with resectable CRCLM.

Dataset Information

Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.

Publications

Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets